 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Companys 2021 accomplishments across strategic priorities and key upcoming catalysts at the 40th Annual J.P. Morgan He 